RecruitingMultiple Myeloma
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Eligible age
18+ yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).
Sponsor: Celgene
You may qualify if…
- ✓ Age ≥18 with history of relapsed and refractory multiple myeloma (RRMM) treated with 2 to 4 prior lines of anti-myeloma therapy (Phase 1) or 1 to 3 prior lines of anti-myeloma therapy (Phase 2).
- ✓ Measurable MM by local laboratory.
- ✓ Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.
- ✓ Adherence to contraception requirements.
You may not qualify if…
- ✕ Prior treatment with mezigdomide.
- ✕ Prior treatment with T cell engaging or T cell engager (TCE).
- ✕ Prior treatment with B cell-maturation antigen (BCMA)-targeting therapy, with the exception of participants who have received autologous BCMA-targeted CART-cell therapy\> 6 months from the start of study therapy
- ✕ Other protocol-defined Inclusion/Exclusion criteria apply.
Where it's recruiting
Source: ClinicalTrials.gov · NCT06988488 · last updated 2026-05-28